Amplification and protein over-expression of the neu/HER-2/c-erbB-2 protooncogene in human breast carcinomas: relationship to loss of gene sequences on chromosome 17, family history and prognosis
1990

c-erbB-2 Gene Amplification in Breast Cancer

Sample size: 113 publication Evidence: moderate

Author Information

Author(s): A.-L. B0rresen, L. Ottestad, A. Gaustad, T.I. Andersen, R. Heikkila, T. Jahnsen, K.M. Tveit, J.M. Nesland

Primary Institution: Institute for Cancer Research, The Norwegian Radium Hospital

Hypothesis

Does c-erbB-2 gene amplification correlate with aggressive tumor behavior and prognosis in breast cancer?

Conclusion

The study found that c-erbB-2 gene amplification is associated with a higher recurrence rate in breast cancer patients.

Supporting Evidence

  • 22.5% of primary tumors showed c-erbB-2 gene amplification.
  • 50% of metastases had c-erbB-2 amplification.
  • Amplified tumors had a significantly higher recurrence rate.
  • All amplified tumors were of the invasive ductal type.
  • 55% of tumors showed allele loss on chromosome 17p.

Takeaway

This study looked at breast cancer tumors to see if a specific gene, c-erbB-2, was more common in aggressive cases. They found that tumors with this gene were more likely to come back after treatment.

Methodology

The study analyzed fresh tumor tissue from 113 breast cancer patients for c-erbB-2 gene amplification and loss of chromosome 17 sequences using Southern analysis and immunostaining.

Potential Biases

Potential biases may arise from the selection of patients and the retrospective nature of family history assessments.

Limitations

The sample size was small, and the observation time for survival data was limited.

Participant Demographics

The study involved Norwegian breast cancer patients, with 89 primary tumors and 24 metastases analyzed.

Statistical Information

P-Value

0.016

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication